葵花药业：盐酸非索非那定口服混悬液获得药品注册证书

Core Viewpoint - The approval of the oral suspension of Fexofenadine Hydrochloride by the National Medical Products Administration will enhance the company's product pipeline and therapeutic coverage in the allergy treatment sector [1] Group 1 - The company has received a drug registration certificate for Fexofenadine Hydrochloride oral suspension [1] - This product is aimed at the allergy treatment market, indicating a strategic expansion in the company's offerings [1] - The company plans to accelerate the mass production and market launch of this product, facilitating the rapid conversion of research outcomes into marketable products [1]